Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | EBP | Q15125 | 6/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | DHCR7 | Q9UBM7 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10879788 | 0.85 | KMT2A (0.53) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL6009065 | 0.85 | CYP2D6 (0.51) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL8707174 | 0.82 | EBP (0.56) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL8707721 | 0.81 | EBP (0.60) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL4314565 | 0.80 | EBP (0.53) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL10880305 | 0.79 | MEN1 (0.52) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL10356744 | 0.76 | CYP2D6 (0.58) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| Tribromoethanol SCHEMBL11621823 | 0.76 | CYP2D6 (0.52) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL2896442 | 0.75 | CYP2D6 (0.54) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL330094 | 0.74 | SIGMAR1 (0.67) | CYP2D6HTTCYP1A2LTA4HCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734208-B2 | ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS | NEORX CORPORATION | 2004-05-11 | — | — | US | disclosed |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | CYP2D6 4879/4885HTT 2466/4885CYP1A2 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.